Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T‐cell lymphoma and cutaneous T‐cell lymphoma
Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 269-270
10.1002/hon.3164_181